ClinConnect ClinConnect Logo
Search / Trial NCT06297577

Clinical Evaluation of Injectable Alb-PRF in the Management of Intrabony Defect in Stage-III Periodontitis Patients

Launched by CAIRO UNIVERSITY · Feb 29, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Albumin Platelet Rich Fibrin (Alb Prf) Minimally Invasive Surgical Technique (Mist) Stage 3 Periodontitis Intrabony Defect

ClinConnect Summary

This clinical trial is studying two treatments for patients with advanced gum disease, specifically those with deep holes in their jawbone caused by periodontitis. The researchers want to find out if a new treatment called Injectable Albumin Platelet Rich Fibrin (Alb-PRF) works better when used alongside a minimally invasive surgical technique compared to a standard treatment known as Platelet Rich Fibrin (PRF). Both treatments aim to help heal the damaged areas and improve dental health.

To be eligible for this study, participants must be at least 18 years old and have specific types of deep gum defects in their teeth. They should not have received any antibiotics or other treatments for gum disease in the last six months and must be in good overall health. Participants will need to sign a consent form to join and should be motivated to maintain good oral hygiene. If you’re interested in participating, it’s important to know that the study is not yet recruiting, so keep an eye out for updates!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Stage III periodontitis patient having at least one tooth with 2-wall, 3-wall, or combined 2- to 3-wall intrabony defect ≥3 mm in depth (assessed by bone sounding, radiographic examination) with clinical attachment level (CAL) ≥5mm and probing pocket depth (PPD) ≥6 mm with no defect extending to a root furcation area.
  • 2. Vital teeth.
  • 3. No history of intake of antibiotics or other medications affecting the periodontium in the previous 6 months.
  • 4. No periodontal therapy carried out in the past 6 months.
  • 5. Ability to sign an informed consent form.
  • 6. Patients age ≥18 years old.
  • 7. Patients who are cooperative, motivated, and hygiene conscious.
  • 8. Systemically free according to Cornell Medical Index.
  • Exclusion Criteria:
  • 1. Patient undergoing orthodontic treatment.
  • 2. Pregnant females or breast feeding.
  • 3. Smokers.
  • 4. Teeth mobility greater than grade I.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Patients applied

0 patients applied

Trial Officials

Manal Hosny, Professor

Study Director

Cairo University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported